ClinicalTrials.gg
CompletedNCT05476341Updated Jul 27, 2022

A Phase I Clinical Trial of Bevacizumab Injection

A Phase 1 interventional study of Bevacizumab injection and Bevacizumab injection(Avastin) in Rectal Cancer, Lung Cancer and Ovarian Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 3 months after the study started (first participant enrolled Apr 2017, registered Jul 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies testing bevacizumab in Rectal Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. Bevacizumab · Rectal Neoplasms.

Enrollment
19th of 80
98 · median 45
Started
2017
the only one that year
Phase 1
11 of 83
none open now
Registered
73rd of 83
by date

Among the 83 studies testing bevacizumab in Rectal Neoplasms, this one is the 19th largest by enrollment of the 80 interventional ones that give a count, is the only one that started in 2017, is one of 11 in phase 1, and was the 73rd registered.

Rectal Neoplasms

2,402 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

8 of the 83 studies testing bevacizumab in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 405 Rectal Neoplasms studies recruiting now, 210 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing bevacizumab in Rectal Neoplasms, or all of them as a file.
02

Study summary

Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd Biological similar drugs. Its mechanism is to prevent VEGF from binding to its natural receptor VEGFR, inhibit the proliferation and activation of vascular endothelial cells, and play an anti angiogenesis and anti-tumor role by binding with VEGF. A randomized, double-blind, single dose, parallel comparison of bevacizumab injection and Avastin is planned The phase I clinical study on the similarity of pharmacokinetics and safety of traditional Chinese medicine in healthy male volunteers aims to compare bevacizumab injection with Avastin The similarity of pharmacokinetics, tolerance, safety and immunogenicity.

03

Conditions studied

  • Rectal Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Glioblastoma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Fully understand the purpose of the test, and basically understand the pharmacological effects and possible adverse reactions of the research drugs; Voluntarily sign written in accordance with the spirit of the Helsinki declaration.
  • 2 Healthy male subjects aged ≥ 18 and ≤ 65.
  • 3 Weight ≥ 50 kg and ≤ 80 kg, (BMI) ≥ 18 and ≤ 28kg/m2.
  • 4 Each system examination index is within the normal range, or the examination result is abnormal, but it is judged by the researcher to be of no clinical significance.
  • 5 The subjects agreed to use reliable for themselves and their partners during the study period and within 6 months after the infusion of the study drug(such as abstinence, sterilization, contraceptive pills, injection of contraceptive medroxyprogesterone or subcutaneous implantation contraception, etc).

Exclusion criteria

Exclusion Criteria:

  • 1 Have a history of hypertension or abnormal blood pressure during screening / baseline measurement(Repeated measurements on the same day confirmed that systolic blood pressure [SBP] > 140 mmHg and / or diastolic blood pressure [DBP] > 90 mmHg).
  • 2 proteinuria (routine urine examination, urine protein 2+ and above) or history of proteinuria assessed by the investigator.
  • 3 Have received any antibody or protein therapy targeting VEGF or VEGF receptor in the past 1 year.
  • 4 Used any biological products or vaccinated with within 3 months before the infusion of the study drug, or used any monoclonal antibody within 12 months.
  • 5 Have hereditary bleeding tendency or coagulation dysfunction, or have a history of thrombosis or bleeding.
  • 6 Have a history of gastrointestinal perforation or fistula.
  • 7 Unhealed wound ulcer or fracture, or major surgery within the first 2 months of randomization, or major surgery expected during the study period or within 2 months after the end of the study.
  • 8 Use prescription or over-the-counter drugs or nutritional health products, and the use time is within 5 half lives of the drugs or nutritional health products or within 2 weeks before the use of the study drugs (the time limit is whichever is longer).Herbal health products should be stopped 28 days before using the study drug.
  • 9 surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody or syphilis antibody are tested positive.
  • 10 Known allergy to bevacizumab or any of its .
  • 11 People with known history of allergic diseases or allergic constitution.
  • 12 There was a history of blood donation 3 months before the infusion of the study drug.
  • 13 Have been treated with any other research drugs or participated in another intervention clinical trial within 2 months before screening.
  • 14 Have a history of alcohol or drug abuse within 12 months before screening; The subjects were unable to quit drinking within 72 hours before administration and throughout the trial.
  • 15 Have a history of mental illness.
  • 16 Subjects whose spouses plan to conceive.
  • 17 Unable to follow the protocol requirements to complete the study during the study.
  • 18 Other researchers think it is not suitable to be included in the group
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Bevacizumab injection

    On the first day, bevacizumab injection was given, 3mg/kg each time, diluted to 100ml of 0.9% sodium chloride injection, mixed evenly, and then intravenous infusion for 90 minutes (±15 minutes).

    Drug: Bevacizumab injection

  • Active comparator
    Bevacizumab injection(Avastin)

    On the first day, Avastin injection was given, 3mg/kg of which was diluted to 100ml of 0.9% sodium chloride injection. After mixing evenly, it was infused intravenously for 90 minutes (±15 minutes).

    Drug: Bevacizumab injection(Avastin)

Interventions

  • Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor

  • DrugBevacizumab injection(Avastin)

    Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor

06

What researchers measure

Primary outcomes

  1. Plasma concentration-area under time curve(AUC0-t)

    Area under the blood concentration time curve from 0 hour to the collection time t of the last measurable concentration

    Time frame: Within 30 minutes before administration to 1680 hours (day 71)

Secondary outcomes

  1. Plasma concentration-area under time curve(AUC0-∞)

    Area under the blood concentration time curve from 0 hour to inf (infinity)

    Time frame: Within 30 minutes before administration to 1680 hours (day 71)

  2. Peak concentration (Cmax)

    Maximum plasma concentration observed after administration

    Time frame: Within 30 minutes before administration to 1680 hours (day 71)

  3. Incidence of adverse events

    Incidence of adverse events assessed by CTCAE v4.0

    Time frame: Within 30 minutes before administration to 1680 hours (day 71)

  4. Number of adverse events related to the study drug

    Number of adverse events evaluated by CTCAE v4.0

    Time frame: Within 30 minutes before administration to 1680 hours (day 71)

  5. Incidence of adverse events related to the study drug

    Incidence of study drug-related adverse events assessed by CTCAE v4.0

    Time frame: Within 30 minutes before administration to 1680 hours (day 71)

  6. ADA positive rate

    When anti drug antibody (ADA) is positive, neutralizing antibody (NAB) test is performed

    Time frame: Within 30 minutes before administration to 1680 hours (day 71)

07

Study locations

1 site
  • Affiliated Hospital of Changchun University of Traditional Chinese Medicine
    Changchun, Jilin 130000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Aug 2017, 4 months.

Of 71 phase 1 interventional studies under Rectal Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 57. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2022
First posted
Jul 27, 2022
StartActual
Apr 6, 2017
Primary completionActual
Aug 18, 2017
CompletionActual
Aug 18, 2017
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05476341
Responsible party
Sponsor
First posted
Jul 27, 2022
Start date
Apr 6, 2017
Primary completion
Aug 18, 2017
Completion
Aug 18, 2017
Last update
Jul 27, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion